Aeterna Zentaris Inc. (AEZS: Quote, AEZ.TO) said that a poster on its novel orally active anticancer PI3K/Erk 1/2 inhibitor, AEZS-136, showed the compound's unique inhibition and excellent activity against PI3K and Erk signaling pathways, as well as being well tolerated.
According to the company, AEZS-136 was well tolerated and showed dose-dependent inhibition of human colon tumor growth of up to 72% in a Hct116 mouse model.
Aeterna Zentaris noted that the anti-proliferative efficacy of AEZS-136 was evaluated in more than 40 human tumor cell lines including breast, ovary, endometrium, multiple myeloma, lung, melanoma, colon, leukemia and prostate cancer cells. In vitro ADMET properties were also widely assessed, while in vivo pharmacokinetics and anti-tumor efficacy was explored.
Juergen Engel, Aeterna Zentaris' President and CEO, commented, "The preclinical data presented yesterday, confirms that AEZS-136 has a unique advantageous dual PI3K /Erk kinase inhibition profile which could prove to be more efficient than single pathway inhibition. Furthermore, AEZS-136 has shown to be well tolerated.
Following these encouraging preclinical data, we are currently moving this promising compound into the clinical development stage."
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org